Key Takeaways:
Medtronic (NYSE: MDT) announced its intent to acquire SPR Therapeutics for approximately $650 million in cash, a strategic move to add temporary peripheral nerve stimulation (PNS) technology to its offerings for chronic pain management. The deal gives Medtronic control of the FDA-cleared SPRINT PNS System, positioning it to intervene earlier in the treatment of a condition affecting nearly 50 million adults in the U.S.
"The addition of temporary peripheral nerve stimulation helps broaden access to neuromodulation and supports patients across more stages of the chronic pain journey with a minimally invasive therapy," Domenico De Paolis, Interim President of Neuromodulation at Medtronic, said.
The acquisition is supported by growing demand for non-opioid pain therapies and strong clinical data. A retrospective review of more than 6,100 patients treated with the SPRINT system found that over 71 percent of participants reported significant pain relief or an improved quality of life. The system provides pain relief through a 60-day treatment that does not require a permanent implant.
For Medtronic, the deal provides an entry into the earlier stages of pain management, a segment where physicians are seeking less invasive options before considering permanent implants or long-term opioid use. The transaction is expected to close in the first half of Medtronic's fiscal year 2027, which began on April 25, 2026.
The core of the acquisition is SPR's SPRINT PNS System. Unlike traditional spinal cord stimulators that are permanently implanted, the SPRINT system uses a thin wire placed near a nerve for a 60-day period to deliver stimulation. This temporary approach is designed to provide sustained pain relief even after the device is removed, offering a crucial option between conservative therapies and more invasive, permanent solutions.
"Together, we will reach more patients helping them find relief earlier in their care journey to reclaim their lives and get back to what matters most," said Maria E. Bennett, CEO of SPR Therapeutics. The system's integration into existing clinical workflows is a key advantage, allowing physicians to offer the therapy without a significant change in practice.
The SPR Therapeutics takeover fits a pattern of targeted acquisitions for Medtronic, which has recently focused on adding specific technologies to its core franchises. The company previously announced deals for CathWorks and Scientia Vascular, valued at $585 million and $550 million respectively, to strengthen its cardiology and neurovascular portfolios. This contrasts with other recent medical device M&A, such as Artivion's acquisition of Endospan for its specialized aortic arch treatment system, highlighting Medtronic's focus on building out its major platforms.
The PNS market is a growing segment within pain management, with competitors like Boston Scientific (NYSE: BSX) and Abbott Laboratories also offering neuromodulation solutions. Medtronic's acquisition of a temporary, FDA-cleared system gives it a differentiated product to compete for patients earlier in their treatment pathway.
This article is for informational purposes only and does not constitute investment advice.
